ArticleFrontiers in microbiology2026
A case-control analysis: changes in gut microbiota composition in children with autism spectrum disorder.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gut microbiota dysbiosis has been increasingly implicated in autism spectrum disorder (ASD), with the gut-brain axis proposed as a potential mechanistic link. However, ASD-specific microbial signatures remain inconsistent across studies, and whether reported associations reflect primary dysbiosis or ASD-related confounders such as dietary restriction and gastrointestinal comorbidities remains debated. Methods: A case-control study was conducted enrolling 54 children with ASD and 46 age- and sex-matched typically developing (TD) children. Full-length 16S rRNA gene sequencing was performed on the PacBio Sequel IIe third-generation platform using universal primers 27F/1492R, generating high-fidelity (HiFi) reads via on-instrument circular consensus sequencing (CCS). Gut microbiota differences were assessed using α- and β-diversity analyses, phylum-level composition, Gut Microbiome Health Index (GMHI), Microbial Dysbiosis Index (MDI), differential abundance testing, and LEfSe analysis. Results: No significant differences were observed in α-diversity between groups, whereas significant differences were identified in β-diversity, GMHI, and MDI. Phylum-level analysis revealed a significantly reduced Bacillota/Bacteroidota ratio in the ASD group. More than 80% of ASD samples had negative GMHI values vs. more than 75% of TD samples with positive values, demonstrating superior discriminative performance compared with traditional diversity indices. Differential abundance analysis identified 15 differentially abundant species: 10 enriched in the TD group, predominantly butyrate-producing bacteria and Bifidobacterium spp., and 5 enriched in the ASD group, predominantly Bacteroides-affiliated taxa. LEfSe confirmed 16 differentially abundant taxa (LDA score ≥ 3.0). Conclusion: Children with ASD exhibited significant differences in gut microbiota composition compared with TD children, characterized by a functional compositional imbalance-systematic depletion of butyrate-producing bacteria and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.